Breadcrumb

[A15-61] Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide - Benefit assessment according to §35a Social Code Book V

Overview

Overview

Commission: Commission awarded on 2015-12-30 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Extract of dossier assessment  [PDF, 783 kB]Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [A18-01] Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (HIV-infected children) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A16-27] Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide – Addendum to Commission A15-61
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2016-04-01 Extract of dossier assessment 783 kBPDFdownload file
2016-04-01 Dossier assessment (German version) 2 MBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


At a glance


Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close